0.45
Acurx Pharmaceuticals Inc stock is traded at $0.45, with a volume of 709.58K.
It is up +0.22% in the last 24 hours and down -37.50% over the past month.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
See More
Previous Close:
$0.449
Open:
$0.41
24h Volume:
709.58K
Relative Volume:
0.12
Market Cap:
$13.23M
Revenue:
-
Net Income/Loss:
$-14.58M
P/E Ratio:
-0.3913
EPS:
-1.15
Net Cash Flow:
$-9.80M
1W Performance:
-4.86%
1M Performance:
-37.50%
6M Performance:
-49.04%
1Y Performance:
-82.28%
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
Name
Acurx Pharmaceuticals Inc
Sector
Industry
Phone
917-533-1469
Address
259 LIBERTY AVENUE, STATEN ISLAND
Compare ACXP with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ACXP
Acurx Pharmaceuticals Inc
|
0.45 | 13.91M | 0 | -14.58M | -9.80M | -1.15 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Acurx Pharmaceuticals Inc Stock (ACXP) Latest News
Acurx Pharmaceuticals Inc. Stock Analysis and ForecastPowerful growth strategies - Jammu Links News
What drives Acurx Pharmaceuticals Inc. stock priceFree Capital Efficiency Planning - Jammu Links News
What analysts say about Acurx Pharmaceuticals Inc. stockFree Risk Assessment Services - Jammu Links News
What risks could impact Acurx Pharmaceuticals Inc. stock performanceFree Stock Market Analysis Courses - Newser
Acurx Pharmaceuticals Holds Annual Meeting and Elections - TipRanks
Acurx Pharmaceuticals shareholders approve board proposals at annual meeting - Investing.com Australia
Acurx Pharmaceuticals shareholders approve board proposals at annual meeting By Investing.com - Investing.com South Africa
Acurx Pharmaceuticals files $50M mixed shelf offering - MSN
How Acurx Pharmaceuticals Inc. stock performs during market volatilityTrend Following Trades - Newser
Acurx Files to Sell 9.16M Shares of Common Stock for Holders - AInvest
What makes Acurx Pharmaceuticals Inc. stock price move sharplyFree Exclusive Group - Newser
Why Acurx Pharmaceuticals Inc. stock attracts strong analyst attentionExplosive Growth Potential - Newser
Acurx Pharmaceuticals (NASDAQ:ACXP) Stock Price Up 3.6% – Here’s Why - Defense World
ACXP SEC FilingsAcurx Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ACXP raises $2.3M via warrant inducement, issues 9.1M new warrants - Stock Titan
Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year? - Yahoo Finance
Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Investors Purchase Large Volume of Acurx Pharmaceuticals Call Options (NASDAQ:ACXP) - Defense World
Acurx Pharmaceuticals Raises Fresh $2.67M Capital: New Antibiotic Development Gets Major Funding Boost - Stock Titan
/C O R R E C T I O N -- Acurx Pharmaceuticals, Inc./ - Yahoo Finance
Acurx Pharmaceuticals Inc (ACXP) Stock: The Story of a 52-Week Stock Range - investchronicle.com
Crude Oil Rises Sharply; Jabil Earnings Top Views - Benzinga
US Stocks Lower; Retail Sales Decline In May - Benzinga
Power Metallic (TSX.V: PNPN) Secures Largest Saudi License Amid June 2025 Gold Surge – Material Gains & More Stocks Inside - FinancialContent
Acurx Pharmaceuticals Soars as Breakthrough Antibiotic Data Hits the Headlines - RagingBull
Banco Santander S.A. ADR Inc. (SAN) Price Performance: A Comparative Analysis with Competitors - investchronicle.com
Why Is Acurx Pharmaceuticals Stock (ACXP) Up 250% Today? - TipRanks
Breakthrough: New Antibiotic Achieves 94% Cure Rate Against C. Difficile, Outperforms Standard Treatment - Stock Titan
(PDF) A unique inhibitor conformation selectively targets the DNA polymerase PolC of Gram-positive priority pathogens - researchgate.net
Mirum Pharmaceuticals Expands Team with 10 New Hires, Grants $5.7M Stock Options Package - Stock Titan
TJX Maintains Strong Dividend Program: Top Retail Chain Announces $0.425 Per Share Payout - Stock Titan
New to The Street's Documentary Specials Break Records: IMG Academy Surpasses 126,000 Views in Just 12 Days - Akron Beacon Journal
Acurx announces presentation of results for DNA pol IIIC inhibitors - TipRanks
Acurx Pharmaceuticals Announces Presentation Of Results From Leiden University Medical Center Public-Private Partnership For Its DNA pol IIIC Inhibitors - marketscreener.com
Acurx (ACXP) Advances Antibiotic Candidate for C. difficile Treatment | ACXP Stock News - GuruFocus
Warner Bros. Discovery to split into two companies, dividing cable and streaming services - WFMZ.com
Breakthrough: New Antibiotic Class Shows Promise Against Drug-Resistant C. DifficilePhase 3 Ready - Stock Titan
Clostridium Difficile Infections Pipeline 2025: MOA and ROA - openPR.com
Popular Inc Delivers Double Income Stream: New Preferred Stock Dividend Plus Trust Securities Distribution - Stock Titan
Exclusive: Aptar Leadership Team Set for Strategic Updates at Major Investment Conferences - Stock Titan
Medical Properties Trust Dividend Alert: $0.08 Per Share Payable July 17Key Dates Inside - Stock Titan
Exicure Faces Nasdaq Delisting Risk: 60 Days to Submit Compliance Plan for Late Q1 Filing - Stock Titan
Ardent Health Partners Streamlines Brand Identity: What the New Corporate Name Means for Investors - Stock Titan
Chikungunya wins boost Valneva; overall infectious disease stocks fall - BioWorld MedTech
ACXP Stock: Selling Stockholder to Offload Shares with No Procee - GuruFocus
Acurx Pharmaceuticals Inc Stock (ACXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acurx Pharmaceuticals Inc Stock (ACXP) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Sailer Carl | Director |
Jan 06 '25 |
Buy |
1.01 |
24,631 |
25,000 |
137,183 |
LUCI DAVID P | President and CEO |
Jan 06 '25 |
Buy |
1.01 |
49,261 |
50,000 |
1,097,458 |
Donohue James J. | Director |
Jan 06 '25 |
Buy |
1.01 |
9,852 |
10,000 |
22,352 |
DELUCCIA ROBERT J | Director |
Jan 06 '25 |
Buy |
1.01 |
49,261 |
50,000 |
1,010,196 |
DEAN JACK H | Director |
Jan 06 '25 |
Buy |
1.01 |
9,852 |
10,000 |
21,776 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):